NEUROLOGY 1989;39:1631
© 1989 American Academy of Neurology
Use of antithrombotic drugs in the treatment of acute ischemic stroke
A survey of neurologists in practice in the United States
E. E. Marsh, III, MD,
H. P. Adams, Jr., MD,
J. Biller, MD,
P. Wasek, BA,
K. Banwart, RN,
V. Mitchell, RN and
R. Woolson, PhD
From the Division of Cerebrovascular Diseases, Department of Neurology (Drs. Marsh, Adams, and Biller, Ms. Banwart, and Ms. Mitchell) and the Division of Biostatistics, Department of Preventive Medicine (Ms. Wasek and Dr. Woolson), University of Iowa College of Medicine, Iowa City, IA.
In an attempt to determine the opinions and practices of neurologists regarding the use of antithrombotic drugs in the treatment of acute ischemic stroke, we conducted a survey of 349 randomly selected neurologists from throughout the United States. Responses were received from 247 (71%), and 219 identified themselves as primary or consulting physicians for patients with acute ischemic stroke. During the previous 12 months, these 219 physicians estimated that they had seen a total of 14,636 patients within 24 hours of acute ischemic stroke, and 22% of these patients were treated with heparin. The most frequently reported indications were prevention of recurrent cerebral embolism (82% of physicians) and progressing stroke (70%). Despite the frequent use of heparin, only 6.4% of neurologists felt that it has been shown to be effective, and 16.4% felt that it has been shown to be of no value. The primary concern about the use of heparin was lack of proven efficacy in 48% and safety concerns in 41%. Results of a future trial testing the efficacy of antithrombotic drugs would be useful for most neurologists in their management of patients with acute or progressing ischemic stroke.
Address correspondence and reprint requests to Dr. Marsh, Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242.
Received March 28, 1989. Accepted for publication in final form May 31, 1989.
This article has been cited by other articles:
|
|
|
|
 
P. M.W. Bath, L. Zhao, and S. Heptinstall
Current status of stroke prevention in patients with atrial fibrillation
Eur. Heart J. Suppl.,
May 1, 2005;
7(suppl_C):
C12 - C18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W-P. Schmidt, P. Heuschmann, D. Taeger, H. Henningsen, H-J. Buecker-Nott, and K. Berger
Determinants of IV heparin treatment in patients with ischemic stroke
Neurology,
December 28, 2004;
63(12):
2407 - 2409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Packard, C. S. Kase, A. S. Aly, and G. D. Barest
"Computed Tomography-Negative" Intracerebral Hemorrhage: Case Report and Implications for Management
Arch Neurol,
August 1, 2003;
60(8):
1156 - 1159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Wang, L. Xu, H. Wang, R. Grzanna, Y. Zhan, R. M. Knabb, J. M. Luettgen, T. A. Bozarth, R. A. Galemmo, P. C. Wong, et al.
Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembolic Stroke in Rats
Stroke,
February 1, 2003;
34(2):
468 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Al-Sadat, M. Sunbulli, and S. Chaturvedi
Use of Intravenous Heparin by North American Neurologists: Do the Data Matter?
Stroke,
June 1, 2002;
33(6):
1574 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Adams Jr
Emergent Use of Anticoagulation for Treatment of Patients With Ischemic Stroke
Stroke,
March 1, 2002;
33(3):
856 - 861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Thulborn, T. S. Gindin, D. Davis, and P. Erb
Comprehensive MR Imaging Protocol for Stroke Management: Tissue Sodium Concentration as a Measure of Tissue Viability in Nonhuman Primate Studies and in Clinical Studies
Radiology,
October 1, 1999;
213(1):
156 - 166.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. A. Swanson
Intravenous heparin for acute stroke: What can we learn from the megatrials?
Neurology,
June 1, 1999;
52(9):
1746 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Publications Committee for the Trial of ORG 10
Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled Trial
JAMA,
April 22, 1998;
279(16):
1265 - 1272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Goldstein, A. J. Bonito, D. B. Matchar, P. W. Duncan, and G. P. Samsa
US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke: Medical Therapy in Patients With Carotid Artery Stenosis
Stroke,
September 1, 1996;
27(9):
1473 - 1478.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Kay, K. S. Wong, Y. L. Yu, Y. W. Chan, T. H. Tsoi, A. T. Ahuja, F. L. chan, K. Y. Fong, C. B. Law, A. Wong, et al.
Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke
N. Engl. J. Med.,
December 14, 1995;
333(24):
1588 - 1594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Counsell, C. Warlow, P. Sandercock, H. Fraser, and J. van Gijn
The Cochrane Collaboration Stroke Review Group : Meeting the Need for Systematic Reviews in Stroke Care
Stroke,
March 1, 1995;
26(3):
498 - 502.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Camerlingo, L. Casto, B. Censori, B. Ferraro, G. C. Gazzaniga, B. Cesana, and A. Mamoli
Immediate Anticoagulation With Heparin for First-Ever Ischemic Stroke in the Carotid Artery Territories Observed Within 5 Hours of Onset
Arch Neurol,
May 1, 1994;
51(5):
462 - 467.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. C. Anderson
How Twin Cities Neurologists Treat Ischemic Stroke: Policies and Trends
Arch Neurol,
October 1, 1993;
50(10):
1098 - 1103.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. F. Rothrock and R. G. Hart
Antithrombotic Therapy in Cerebrovascular Disease
Ann Intern Med,
December 1, 1991;
115(11):
885 - 895.
[Abstract]
[PDF]
|
|
|
|
